No Cuts, No Ceasefire, No Clarity: The Macro Wall Investors Are Staring Down

The macro environment got more complicated overnight. President Trump’s prime-time address Wednesday signaling fresh US military strikes on Iran within the next two to three weeks sent oil prices surging past $110 a barrel and triggered a broad selloff in US Treasuries — a combination that has real consequences for the small and microcap companies ChannelChek covers every day.

US two-year yields climbed as much as six basis points to 3.86%, while 10-year yields rose as high as 4.38% before trimming some of the move. The dollar strengthened against all its Group-of-10 peers. Global bond markets followed suit, with Australian and New Zealand 10-year yields rising more than 10 basis points and European traders pricing in three quarter-point ECB rate hikes this year.

The Fed Is Now Boxed In

Before the Iran conflict escalated in late February, markets had priced in more than two Federal Reserve rate cuts in 2026. Those expectations have been completely erased. Overnight index swaps now reflect a Fed that stays on hold for the remainder of the year — a meaningful pivot that ripples directly into how investors value growth-oriented, capital-dependent smaller companies.

The inflation data is not helping. The ISM’s gauge of prices paid for manufacturing inputs climbed to 78.3 in March, remaining at its highest level since mid-2022. That number landed just as oil was spiking, reinforcing the concern that energy-driven inflation isn’t transitory — it’s structural for as long as the Strait of Hormuz remains closed or threatened.

Fed Chair Jerome Powell said earlier this week that longer-term inflation expectations appear to be in check, but acknowledged officials are closely monitoring the situation. The market isn’t waiting for clarity. The arm wrestle between inflation fear and growth concern — as Westpac’s Martin Whetton put it — is now the defining tension in fixed income, and it’s not resolving anytime soon.

Why This Matters for Small and Microcap

Small and microcap companies feel rate environment shifts more acutely than large caps for a straightforward reason: they depend more heavily on external financing. When rate cut expectations evaporate and credit conditions tighten, the cost of capital rises and the timeline for profitability gets scrutinized harder. Biotech companies burning cash toward clinical readouts, small industrials refinancing debt, and emerging growth companies looking to raise equity — all of them operate in a tougher environment when the Fed is frozen and bond yields are climbing.

The growth risk is equally significant. Higher oil prices function as a tax on consumers and businesses alike. Money managers at PIMCO and JPMorgan Asset Management have already signaled they’re positioning for an economic slowdown that will eventually drive a bond market rebound — which would suggest yields come back down, but only after a growth scare first. That sequence — inflation now, slowdown later — is historically difficult for smaller companies to navigate.

The Geopolitical Wildcard

What makes this environment particularly hard to trade is the binary nature of the catalyst. A ceasefire announcement could reverse oil prices and Treasury yields in a session. But as M&G Investments’ Andrew Chorlton noted, even a ceasefire is likely to be fragile, and markets may be underestimating the inflationary consequences of a conflict that could continue to flare up unpredictably. The risk premium, he argued, should be higher than where markets are currently pricing it.

For investors focused on small and microcap names, the near-term playbook is one of selectivity — companies with strong balance sheets, near-term catalysts, and limited macro exposure are better positioned to weather the volatility than those dependent on a benign rate environment to execute their growth strategy.

The macro has reasserted itself. Navigate accordingly.

Summit Midstream Corp (SMC) – Private Placement Financing Strengthens Balance Sheet and Enhances Financial Flexibility


Thursday, April 02, 2026

Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Private placement financing. Summit Midstream announced a private placement of 1,351,351 shares of its common stock with an affiliate of Tailwater Capital LLC at a price of $31.08 per share to raise $42.0 million. Summit intends to use the net proceeds to reduce borrowings under the company’s asset-based lending credit facility and to fund organic growth capital projects. Following the transaction, Tailwater and its affiliated entities are expected to own ~39% of Summit’s outstanding equity.

Updating estimates and valuation. Following the financing, Summit will have 13.8 million common shares, along with 6.5 million Class B shares outstanding for a total of 20.3 million shares. We have made no changes to our revenue or EBITDA estimates, although the higher share count has a minor impact on per share estimates and lowers our valuation per share to $46.00 from $48.50.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Great Lakes Dredge & Dock (GLDD) – Acquisition by Saltchuk Completed


Thursday, April 02, 2026

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Acquisition Completed. The acquisition of Great Lakes Dredge & Dock by Saltchuk Resources was completed on April 1st. Announced on February 11th, Saltchuk paid $17/sh for the outstanding GLDD stock, an enterprise value of approximately $1.5 billion.

Tender Offer. As of the expiration of the tender offer, approximately 53,738,558 shares of Great Lakes common stock were validly tendered and not validly withdrawn pursuant to the tender offer, representing approximately 79.88% of the issued and outstanding shares of Great Lakes common stock. As a result of the completion of the transaction, prior to the opening of trading on the NASDAQ on April 1, 2026, all shares of Great Lakes common stock ceased trading, and all shares of Great Lakes common stock will subsequently be delisted from NASDAQ and deregistered under the Securities Exchange Act of 1934.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

GoHealth (GOCO) – Reset Deepens, Long-Term Thesis Intact


Thursday, April 02, 2026

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Jacob Mutchler, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Results weaker than expected. Full year 2025 revenue of $361.9 million was well below our $434.2 million estimate. Management emphasized that the Medicare Advantage market remains in a structural reset heading into 2026, with carriers prioritizing retention, member quality, margin integrity, and disciplined unit economics over enrollment growth. Full year 2025 adj. EBITDA loss estimate of $35.1 million was more than our loss estimate of $29.6 million. 

Strategic reset. The company has deliberately reduced Medicare Advantage enrollments where first-renewal economics were unattractive, prioritizing long-term profitability and appropriate consumer plan fit. Importantly, the company managed cash flow despite the significant revenue drop, a testament to its structural cost restructuring. 


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Direct Digital Holdings (DRCT) – Buy-Side Pivot Gains Traction


Thursday, April 02, 2026

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Jacob Mutchler, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

An in-line Q4. Direct Digital reported Q4 revenue of $8.4M (down 7% YoY), reflecting a sharp decline in sell-side activity, partially offset by strong buy-side growth (+28% YoY). Total company revenues of $8.4 million were better than our $7.7 million estimate. Q4 adj. EBITDA loss was in line with expectations, at $3.6 million versus $3.4 million.  

Buy-side momentum offsetting structural sell-side decline. The primary driver of the quarter was strength in the buy-side segment, supported by improved customer acquisition, higher conversion rates, and increased contribution from returning customers, while the sell-side business experienced significant contraction due to reduced inventory and strategic deprioritization. 


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Commercial Vehicle Group (CVGI) – A CFO Transition


Thursday, April 02, 2026

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

A Transition. Last night, Commercial Vehicle Group announced that Andy Cheung, Chief Financial Officer, will be resigning from his position effective April 15, 2026, to accept a position as Chief Financial Officer of a mid-cap publicly traded company. Angie O’Leary, currently Corporate Controller and Chief Accounting Officer, has been promoted to Interim Chief Financial Officer and will continue to serve as the Corporate Controller and Chief Accounting Officer. At this time, CVG does not intend to initiate a search process to identify a permanent CFO replacement.

Ms. O’Leary. Ms. O’Leary has served as the Company’s Senior Vice President, Corporate Controller, and Chief Accounting Officer since December 2020. Prior to joining the Company, Ms. O’Leary held several leadership roles at Vertiv Holdings Co. from May 2017 to December 2020, including Interim Corporate Controller. Earlier in her career, Ms. O’Leary held several roles at Deloitte & Touche LLP, beginning in January 2004, culminating in the role of Senior Manager – Audit, from August 2010 to May 2017.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Alliance Resource Partners (ARLP) – Updating Estimates and Reiterating Our Outperform Rating


Thursday, April 02, 2026

Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Updating 1Q 2026 estimates. We have lowered our 1Q and FY 2026 EPU estimates to $(0.02) and $2.20, respectively, from $0.61 and $2.60. We have marked-to-market ARLP’s holding of bitcoins, which amounted to 592 bitcoins as of year-end 2025. The price of bitcoin closed at $87,508.83 on December 31, 2025, compared to $68,233.31 on March 31. We anticipate that the value of digital assets in Q1 2026 could decrease by approximately $11.4 million if all bitcoins were held through the end of the first quarter. Because it would represent a non-cash unrealized loss, it has no impact on our adjusted EBITDA estimate. Moreover, our EPU estimate reflects a non-cash impairment charge of $43 million related to a decision to cease longwall production at the Mettiki Mining complex, although it has no impact on our adjusted EBITDA estimate.

FY 2026 estimates. We have also adjusted the cadence of coal sales throughout the year, with lower volumes in the first quarter, along with higher segment adjusted EBITDA expense per ton. While we have lowered our FY 2026 EPU estimates, our adjusted EBITDA estimate declined only modestly to $708.3 million from $708.4 million due, in part, because our estimates reflect greater tonnage in the second half of the year when adjusted EBITDA expense per ton is lower, and margins are stronger. Quarterly coal sales volume is expected to be lowest in the first quarter, increase modestly in the second, and peak in the back half as longwall move disruptions abate.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

The Pharma Tariff Playbook: How Drug Companies Can Navigate the Administration’s Latest Pricing Push

The Trump administration is preparing to impose tariffs of up to 100% on branded pharmaceutical drugs — but the details buried beneath that headline number tell a more nuanced story, one that comes with multiple off-ramps for companies willing to engage. According to a draft document obtained by CNBC, the proposal is not final, and the framework is structured less as a blanket penalty and more as a tiered system designed to reward companies that move quickly and strategically.

Understanding the structure matters more than reacting to the headline.

How the Framework Actually Works

Under the draft proposal, patented medications and their active pharmaceutical ingredients would face a 100% tariff — but that rate applies specifically to companies that have neither struck deals with the administration nor committed to onshoring US manufacturing. Companies that are actively moving production to the United States would face a significantly lower 20% rate, with a four-year runway before that escalates. Companies that have already executed pricing deals with the Department of Health and Human Services — or are currently in active negotiations — are exempt from additional tariffs entirely. Generic drugs face zero new tariffs under the proposal. Separate negotiated rates also exist for the EU, Japan, South Korea, Switzerland, and the UK through bilateral arrangements.

The architecture of this plan is deliberate. The 100% figure is the ceiling for the least cooperative scenario, not the baseline.

The Early Movers Are Already Protected

Since November, more than a dozen major drugmakers — including Eli Lilly, Pfizer, and Novo Nordisk — have signed agreements with the Trump administration under the “most favored nation” pricing policy, which ties US drug prices to lower international rates. Those deals came with a three-year tariff exemption, meaning the companies that read the room early are sitting out this round entirely. Lilly in particular has had an extraordinarily active week — closing a $6.3 billion acquisition of Centessa Pharmaceuticals and receiving FDA approval for its oral GLP-1 drug Foundayo — operating from a position of policy stability that its peers without deals don’t currently enjoy.

The Roadmap for Smaller Companies

For small and microcap biopharma companies, the key takeaway is that the exemption pathways are real and accessible. The administration has structured this to incentivize negotiation, not to punish innovation. Companies currently in active HHS discussions face no additional tariffs — which means initiating that conversation sooner rather than later is the most direct hedge available.

The generic drug exemption also provides meaningful relief for a significant portion of the smaller specialty pharma universe. And for companies earlier in their development cycle — clinical-stage biotechs without commercial products yet — the immediate operational impact is limited while the policy landscape continues to develop.

The onshoring incentive embedded in the framework also opens a longer-term strategic conversation. Federal policy is clearly moving toward rewarding domestic manufacturing investment, and companies that begin building that into their operational planning now will be better positioned competitively as the rules solidify.

The Bigger Picture

This proposal is part of a broader administration push to restructure how drugs are priced and where they are made in the United States. The direction of travel is clear even if the final details are not. For biopharma companies of every size, the companies that treat this as a strategic planning exercise rather than a political headline will be the ones best positioned when the policy finalizes.

The playbook exists. The question is who runs it first.

Korsana Biosciences Emerges from Cyclerion Merger with $380 Million and a Next-Generation Shot at Alzheimer’s

A small-cap reverse merger is giving birth to one of the better-funded Alzheimer’s plays to hit the public markets in recent memory. Cyclerion Therapeutics (Nasdaq: CYCN) and privately-held Korsana Biosciences announced a definitive all-stock merger agreement that will effectively hand the Nasdaq listing to Korsana, with the combined company rebranding as Korsana Biosciences and trading under the new ticker “KRSA.”

The deal comes packaged with serious capital behind it. Concurrent with the merger, Korsana secured approximately $380 million in a heavily oversubscribed private financing round led by Fairmount and Venrock Healthcare Capital Partners, with participation from a deep bench of institutional names including General Atlantic, Wellington Management, RA Capital Management, RTW Investments, and J.P. Morgan Life Sciences Private Capital, among others. That kind of syndicate doesn’t assemble around a science project — it assembles around conviction.

The combined company’s cash position at closing is expected to fund operations into 2029, providing runway through multiple critical clinical milestones.

The Science Behind the Capital

Korsana’s lead program, KRSA-028, is a next-generation shuttled monoclonal antibody targeting amyloid beta for the treatment of Alzheimer’s disease — the same mechanism that underpins approved therapies like lecanemab and donanemab, but engineered to address their most significant limitations.

The differentiation lies in Korsana’s proprietary Therapeutic Targeting platform, known as THETA™. The platform incorporates clinically validated transferrin receptor (TfR1) and Fc engineering designed to dramatically improve brain delivery — getting more drug where it needs to go. KRSA-028 was specifically designed to increase amyloid plaque clearance while reducing the rate of amyloid-related imaging abnormalities (ARIA), a safety concern that has complicated the commercial rollout of first-generation anti-amyloid therapies. It also targets a low-volume subcutaneous administration route, a meaningful convenience advantage over current IV-infusion dependent treatments.

Korsana is the seventh company to launch with assets discovered through Paragon Therapeutics, a track record that adds credibility to the platform’s pedigree.

Key Milestones on the Horizon

The $380 million in financing is structured to carry Korsana through two pivotal data readouts: Phase 1 healthy volunteer data from KRSA-028 expected in mid-2027, and interim proof-of-concept data measuring amyloid plaque clearance in Alzheimer’s patients expected by the end of 2027. If those readouts deliver, the story accelerates significantly.

The Mechanics of the Deal

Under the merger terms, existing Cyclerion shareholders will own approximately 1.5% of the combined company, with Korsana stockholders — inclusive of the private placement participants — holding the remaining 98.5%. That’s a near-total reset of the cap table, which is standard for this type of reverse merger structure where the private company is clearly the operating entity driving the deal.

The transaction has been approved by both boards and is expected to close in the third quarter of 2026, subject to shareholder approvals and customary regulatory conditions including HSR clearance.

Wedbush Securities acted as exclusive strategic financial advisor to Korsana. Jefferies, TD Cowen, Stifel, and UBS served as placement agents. Ropes & Gray advised Cyclerion.

For small and microcap investors, the Korsana story is worth tracking closely. A well-capitalized, differentiated Alzheimer’s platform with a clear clinical timeline and institutional backing is exactly the kind of setup that can move quickly once data starts flowing.

Cadrenal Therapeutics (CVKD) – Cadrenal Reports FY2025 With Clinical Progress


Wednesday, April 01, 2026

Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Progress On CAD-1005 Reported With FY2025 Results. Cadrenal reported a loss for 4Q25 of $3.0 million or $(1.42) per share and a FY2025 loss of $13.2 million or $(6.64) per share. Importantly, it recently held its End-Of-Phase 2 meeting with the FDA to receive guidance for the planned Phase 3 trial for CAD-1005 in HIT (heparin-induced thrombocytopenia). The company had cash and equivalents of $4.0 million on December 31, 2025.

Lead Indication Reported Phase 2 Data. As discussed in our Research Note on February 25, Cadrenal reported results from its Phase 2 study of CAD-1005 in HIT. The trial was designed to show CAD-1005 improved platelet recovery and tested platelet count recovery as a biomarker for thrombosis and outcome. The data did not show a correlation between platelet count normalization and thrombotic events, but did show an important reduction in thrombotic events exceeding 25% in the CAD-1005 treatment arm compared with placebo.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

NeuroSense Therapeutics Ltd. (NRSN) – NeuroSense Reports FY2025 With Outlook For The Year


Wednesday, April 01, 2026

Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

FY2025 Reported With PrimeC Progress Review. NeuroSense reported a loss for FY2025 of $11.1 million or $(0.44) per share. The company gave updates to its ongoing PrimeC development programs and expected milestones for the coming year in ALS and Alzheimer’s disease. As of December 31, 2025, NeuroSense had cash of approximately $0.2 million.

Phase 3 In ALS Has Received FDA Clearance. During November 2025, NeuroSense received FDA clearance to initiate the Phase 3 trial in ALS. The company has completed commercial-scale manufacturing and continues to prepare for the Phase 3 trial, which we expect to begin later in FY2026.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

MAIA Biotechnology (MAIA) – MAIA Reports Two-Year Survival Data At Medical Conference


Wednesday, April 01, 2026

Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

New Data Presented Shows Long-Term Survival. MAIA presented data from its Phase 2 THIO-101 trial at the European Lung Cancer Congress 2026 (ELCC) held recently in Copenhagen, Denmark. The presentation included data from patients with non-small cell lung cancer (NSCLC) who had relapsed after treatment with standard chemotherapy. Data from 8 patients showed survival exceeding 2 years and greatly exceeded the expected survival for patients at their stage of disease.

Phase 2 Trial Design. THIO-101 was designed in three stages. Part A was basic safety, and Part B was a dose-finding stage. These two stages treated a total of 79 patients. The ongoing Part C is an expansion stage enrolling up to 48 participants in Asia and Europe. The patients are treated with ateganosine (aka THIO) followed by cemiplimab (Libtayo, from Regeneron). 


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

First Phosphate Corp. (FRSPF) – Firing on All Cylinders


Wednesday, April 01, 2026

Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Expanded infill drill program. First Phosphate completed an expanded infill drill program, totaling approximately 40,000 meters, that was launched in October at its Begin-Lamarche property in Saguenay-Lac-St. Jean, Quebec. The drilling program, which was expanded from 30,000 meters of drilling, confirmed continuity of phosphate mineralization across the existing resource horizon and discovered two new mineralized intersects in the Northern and Southern zones.

Updated geological model. The incremental 10,000 meters of drilling was designed to better understand the new intersects and test mineralization at depth in areas across the Northern and Southern zones. The company is processing the full set of drill results from its original and expanded drill program with the goal of updating the geological model in the coming weeks.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.